Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) EBT Margin (2022 - 2026)

bioAffinity Technologies has reported EBT Margin over the past 5 years, most recently at 268.63% for Q1 2026.

  • Quarterly EBT Margin fell 12557.0% to 268.63% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 279.95% through Mar 2026, down 16959.0% year-over-year, with the annual reading at 241.25% for FY2025, 14482.0% down from the prior year.
  • EBT Margin was 268.63% for Q1 2026 at bioAffinity Technologies, down from 196.78% in the prior quarter.
  • Over five years, EBT Margin peaked at 81.37% in Q1 2024 and troughed at 427752.87% in Q3 2022.
  • The 5-year median for EBT Margin is 293.11% (2025), against an average of 42646.84%.
  • The largest YoY upside for EBT Margin was 42698613bps in 2023 against a maximum downside of -205101bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 71380.39% in 2022, then surged by 100bps to 107.12% in 2023, then fell by -25bps to 134.4% in 2024, then crashed by -46bps to 196.78% in 2025, then crashed by -37bps to 268.63% in 2026.
  • Per Business Quant, the three most recent readings for BIAF's EBT Margin are 268.63% (Q1 2026), 196.78% (Q4 2025), and 349.08% (Q3 2025).